Non‑hormonal Management of Moderate to Severe Hot Flashes

First‑Line Pharmacologic Options

• The Endocrine Society strongly recommends SSRIs/SNRIs (paroxetine, venlafaxine, desvenlafaxine), gabapentin, or pregabalin as first‑line therapy for women who cannot or choose not to use menopausal hormone therapy (MHT). 1

SSRIs and SNRIs

• Paroxetine mesylate (7.5–25 mg daily) is the only FDA‑approved non‑hormonal agent for hot flashes and reduces flash frequency by 25–69 %. (Strong recommendation) 2
• Venlafaxine (75–150 mg daily) provides efficacy comparable to paroxetine; in head‑to‑head trials, ≈ 66 % of patients preferred venlafaxine over gabapentin. (Moderate evidence) 1, 3
• Desvenlafaxine (100–150 mg daily), citalopram (10–20 mg daily) and escitalopram (10–20 mg daily) each produce a 27–61 % reduction in a composite hot‑flash score (frequency × severity). (Moderate evidence) 1
• Safety caveat: Paroxetine must be avoided in patients receiving tamoxifen because it markedly impairs conversion to the active metabolite endoxifen. (Strong recommendation) 2

Gabapentin and Pregabalin

• Gabapentin (300–1200 mg daily) given as a single bedtime dose is especially effective for night‑time hot flashes, with sedative effects wearing off by morning. (Moderate evidence) 4, 1
• Day‑time gabapentin can cause intolerable lethargy in some patients. (Moderate evidence) 1
• Pregabalin (75–150 mg twice daily) lowers hot‑flash scores by 65–71 %, compared with a 50 % reduction seen with placebo. (Moderate evidence) 1, 3
• Individual dose requirements for gabapentin and pregabalin vary widely and usually require empiric titration. (Moderate evidence) 1

Second‑Line Option: Clonidine

• Transdermal clonidine patches are reserved for patients who do not respond to or cannot tolerate first‑line SSRIs/SNRIs, gabapentin, or pregabalin. (Weak recommendation) 4, 3
• Clonidine is less effective than first‑line agents and is associated with more adverse effects, including hypotension, light‑headedness, headache, and constipation. (Weak evidence) 4, 3
• Transdermal formulation is preferred over oral tablets because it provides more stable plasma concentrations. (Weak evidence) 4

Comparative Efficacy with Hormone Therapy

• Standard‑dose menopausal hormone therapy remains more effective than any non‑hormonal agent, although head‑to‑head trials have not shown a statistically significant superiority of any specific non‑hormonal regimen. (Moderate evidence) 1, 3

Placebo Response

• The placebo effect in hot‑flash trials averages 30 % (range 4–57 %) and is more pronounced in women with high anxiety or stress levels. (Moderate evidence) 1

Safety and Contra‑indications

SSRIs/SNRIs

• Contra‑indicated in patients with a history of neuroleptic syndrome, serotonin syndrome, or concurrent monoamine‑oxidase inhibitor use. (Strong recommendation) 3
• Use with caution in individuals with bipolar disorder, uncontrolled seizures, hepatic or renal insufficiency, uncontrolled hyponatremia, or poorly controlled hypertension. (Moderate recommendation) 3
• Monitoring: Assess for suicidal thoughts during the first few months of therapy. (Strong recommendation) 3
• Preliminary data suggest a possible increase in bone‑fracture risk with long‑term SSRI/SNRI use. (Low‑quality evidence) 3

Gabapentin / Pregabalin

• May increase suicidal thoughts and behaviors. (Strong recommendation) 3
• Common adverse effects include drowsiness, dizziness, and impaired balance/coordination. (Moderate evidence) 3
• Pregabalin may additionally cause memory and concentration impairment. (Moderate evidence) 3

Non‑Hormonal Management of Postmenopausal Vasomotor Symptoms

Non‑Pharmacologic Measures

• Implement lifestyle modifications—lower ambient temperature (≈ 68 °F), wear adjustable layers, avoid alcohol, spicy foods, and caffeine, pursue weight loss (which can lower hot‑flash frequency by ≈ 26‑40 %), and practice stress‑reduction techniques—to reduce hot‑flash frequency by acting on the narrowed thermoregulatory zone that underlies vasomotor symptoms. 5

First‑Line Pharmacologic Options

SSRIs and SNRIs

• Paroxetine mesylate 7.5‑25 mg daily is the only FDA‑approved non‑hormonal medication for hot flashes and can lower flash frequency by ≈ 25‑69 %. It must be avoided in patients receiving tamoxifen because it markedly impairs conversion to the active metabolite endoxifen. 5
• Venlafaxine 75‑150 mg daily provides efficacy comparable to paroxetine; in head‑to‑head trials, about 66 % of participants preferred venlafaxine over gabapentin, making it the preferred first choice for most women, especially those on tamoxifen. 5
• Safety monitoring for all SSRIs/SNRIs includes: assessing suicidal ideation during the first 2‑3 months of therapy; avoiding use in patients with a history of serotonin syndrome or concurrent MAO‑inhibitor therapy; and exercising caution in individuals with bipolar disorder, uncontrolled seizures, hepatic/renal insufficiency, or poorly controlled hypertension. 5

Gabapentin and Pregabalin

• Gabapentin 300‑1200 mg as a single bedtime dose is particularly effective for predominantly nocturnal hot flashes; daytime dosing often causes intolerable lethargy. Dose titration should start at 300 mg and be adjusted empirically. 5
• Pregabalin 75‑150 mg twice daily reduces hot‑flash scores by ≈ 65‑71 % compared with ≈ 50 % reduction with placebo. 5
• Safety considerations for gabapentin/pregabalin: monitor for emergence of suicidal thoughts and behaviors; common adverse effects include drowsiness, dizziness, and impaired balance/coordination; pregabalin may additionally affect memory and concentration. 5

Selecting the Appropriate First‑Line Agent

• Start venlafaxine 75‑150 mg daily for most women because it combines high efficacy with favorable tolerability and the strongest patient‑preference data. 5
• Choose gabapentin 300‑900 mg at bedtime for women whose hot flashes occur mainly at night or who have concurrent insomnia. 5
• Use citalopram or escitalopram in women receiving tamoxifen, as these agents do not interfere with tamoxifen metabolism. 5

Placebo Effect

• Clinical trials of hot‑flash therapies show an average placebo response of ≈ 30 % (range 4‑57 %), which is more pronounced in women with high anxiety or stress levels. This underscores the importance of supportive care and careful interpretation of treatment benefits. 5

Comparison with Hormone Therapy

• For women who cannot use menopausal hormone therapy (e.g., due to breast cancer history, venous thromboembolism, cardiovascular disease, or personal preference), the non‑hormonal agents described above provide meaningful symptom relief. 5

Common Pitfalls to Avoid

• Do not prescribe sertraline or fluoxetine for hot flashes, as they have shown inconsistent and non‑significant effects. 5
• Never combine paroxetine with tamoxifen because of a severe drug‑interaction that reduces endoxifen formation. 5
• Avoid daytime gabapentin dosing without warning about potential lethargy that can impair daily functioning. 5
• Do not abruptly discontinue SSRIs/SNRIs; taper gradually to prevent withdrawal symptoms. 5

Non‑Hormonal Management of Hot Flashes in Women Receiving Tamoxifen

First‑Line Therapy

• Venlafaxine 75 mg daily (titrated from 37.5 mg after one week) is recommended as the first‑line non‑hormonal agent for moderate‑to‑severe hot flashes and night sweats in patients on tamoxifen. 6
• Venlafaxine does not significantly inhibit CYP2D6, so it does not interfere with the conversion of tamoxifen to its active metabolite endoxifen, unlike paroxetine and fluoxetine. 6, 7
• Discontinuation because of adverse effects occurs in 10–20 % of patients on venlafaxine, which is markedly lower than the ~40 % discontinuation rate observed with clonidine. 6, 8

Alternative First‑Line Options

Gabapentin (Night‑time Predominant Symptoms)

• A single bedtime dose of gabapentin 300–900 mg is effective for women whose hot flashes occur mainly at night. 8
• In tamoxifen users, gabapentin reduces hot‑flash frequency by 49–51 % compared with 21–26 % for placebo. 7, 8
• Gabapentin has no known drug‑interaction with tamoxifen, does not cause sexual dysfunction, and does not produce a withdrawal syndrome. 7, 8
• Side‑effects such as dizziness, drowsiness, and unsteadiness are reported in up to 20 % of patients but typically resolve by week 4. 7, 8

Citalopram / Escitalopram (SSRIs)

• For patients intolerant of venlafaxine, citalopram 10–20 mg daily or escitalopram 10–20 mg daily are safe alternatives that do not inhibit CYP2D6 and therefore do not compromise tamoxifen metabolism. 7

Contraindicated Agents

• Paroxetine and fluoxetine are potent CYP2D6 inhibitors; prescribing them to women on tamoxifen markedly reduces conversion to endoxifen and may diminish cancer‑treatment efficacy. They should be avoided. 6, 7, 8

Second‑Line Option

• Clonidine 0.1 mg daily (oral or transdermal) is reserved for patients who fail or cannot tolerate first‑line agents. It reduces hot flashes by 37–46 % versus 20–24 % with placebo. 6
• Clonidine is associated with a high discontinuation rate (~40 %) due to side‑effects such as dry mouth, insomnia, and drowsiness. 6, 8

Comparative Efficacy (Mean Difference in Daily Hot‑Flash Reduction vs. Placebo)

Data derived from meta‑analysis of randomized trials. 6, 8

Treatment Algorithm

Safety Monitoring

• SSRIs/SNRIs – Avoid in patients with a history of serotonin syndrome, concurrent MAO‑inhibitor use, or poorly controlled bipolar disorder. 6
• Venlafaxine – Taper gradually when discontinuing to prevent withdrawal symptoms. 7
• Gabapentin – No taper is required on discontinuation; no withdrawal syndrome reported. 7, 8

Drug‑Combination Pitfalls

• Combining gabapentin with an SSRI/SNRI provides no additional benefit and should be avoided. 6, 7

Expected Time to Response

• Lack of clinical improvement after four weeks predicts a low likelihood of subsequent response; consider switching therapy at that point. 6, 7

Duration of Therapy

Based on trial follow‑up periods. 6, 8